title: Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients.
abstract: QDMRK was a phase III clinical trial of raltegravir given once daily (QD) (800-mg dose) versus twice daily (BID) (400 mg per dose), each in combination with once-daily coformulated tenofovir-emtricitabine, in treatment-naive HIV-infected patients. Pharmacokinetic (PK) and pharmacokinetic/pharmacodynamic (PK/PD) analyses were conducted using a 2-step approach: individual non-model-based PK parameters from observed sparse concentration data were determined, followed by statistical analysis of potential relationships between PK and efficacy response parameters after 48 weeks of treatment. Sparse PK sampling was performed for all patients (QD, n = 380; BID, n = 384); selected sites performed an intensive PK evaluation at week 4 (QD, n = 22; BID, n = 20). In the intensive PK subgroup, daily exposures (area under the concentration-time curve from 0 to 24 h [AUC(0-24)]) were similar between the two regimens, but patients on 800 mg QD experienced ~4-fold-higher maximum drug concentration in plasma (C(max)) values and ~6-fold-lower trough drug concentration (C(trough)) values than those on 400 mg BID. Geometric mean (GM) C(trough) values were similarly lower in the sparse PK analysis. With BID dosing, there was no indication of any significant PK/PD association over the range of tested PK parameters. With QD dosing, C(trough) values correlated with the likelihood of virologic response. Failure to achieve an HIV RNA level of <50 copies/ml appeared predominantly at high baseline HIV RNA levels in both treatment arms and was associated with lower values of GM C(trough) in the 800-mg-QD arm, though other possible drivers of efficacy, such as time above a threshold concentration, could not be evaluated due to the sparse sampling scheme. Together, these findings emphasize the importance of the shape of the plasma concentration-versus-time curve for long-term efficacy.
authors.affiliation: Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, USA. matthew.rizk@merck.com
authors.forename: Matthew L
authors.initials: ML
authors.lastname: Rizk
authors.forename: Yaming
authors.initials: Y
authors.lastname: Hang
authors.forename: Wen-Lin
authors.initials: WL
authors.lastname: Luo
authors.forename: Jing
authors.initials: J
authors.lastname: Su
authors.forename: Jing
authors.initials: J
authors.lastname: Zhao
authors.forename: Havilland
authors.initials: H
authors.lastname: Campbell
authors.forename: Bach-Yen T
authors.initials: BY
authors.lastname: Nguyen
authors.forename: Peter
authors.initials: P
authors.lastname: Sklar
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Eron
authors.forename: Larissa
authors.initials: L
authors.lastname: Wenning
mesh_terms: D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D017320:HIV Protease Inhibitors; D019438:Ritonavir